Panel pans clinical trials justifying PET coverage

October 6, 2008 Diagnostic Imaging. Panel pans clinical trials justifying PET coverage Poor review of efficacy studies for applications monitored by PET registry disappoints proponents -------------------------------------------------------------------------------- PET imaging proponents reacted with dismay in August when a Centers for Medicare and Medicaid Services advisory panel found data for nine conditionally approved cancer indications of FDG-PET were too ambivalent to support CMS coverage. The nine-member Medicare Evidence Development and Coverage Advisory Committee (MedCAC) heard testimony from the Canadian Evidence-Based Practice Center in Edmonton, AB, and the American National Oncologic PET Registry on Aug. 20 in Woodland, MD.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC